GBP5 and neoplasm: Suppressing GBP5 boosts chemotherapy efficacy in breast cancer, enhancing taxane response and reducing immune evasion, quantifiable through apoptosis assays, immune profiling, or tumor size reduction metrics, aiding treatment monitoring [73].